title: Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
abstract: BACKGROUND
  Aggressive behavior can be a dangerous complication of schizophrenia. Hostility is related to aggression. This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia.
  
  
  METHODS
  We used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility item in a subset of 614 patients who showed at least minimal hostility (a score ≥ 2) at baseline.
  
  
  RESULTS
  The primary analysis of hostility indicated an effect of difference between treatments (F(4,1487) = 7.78, P < 0.0001). Olanzapine was significantly superior to perphenazine and quetiapine at months 1, 3, 6, and 9. It was also significantly superior to ziprasidone at months 1, 3, and 6, and to risperidone at months 3 and 6.
  
  
  CONCLUSIONS
  Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride.
  
  
  CONCLUSIONS
  Olanzapine demonstrated advantages in terms of a specific antihostility effect over the other antipsychotics tested in Phase 1 of the CATIE trial.
authors.affiliation: 1Department of Psychiatry,New York University School of Medicine,New York,New York,USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Volavka
authors.affiliation: 2Department of Psychiatry and Psychotherapy,Semmelweis University,Budapest,Hungary.
authors.forename: Pál
authors.initials: P
authors.lastname: Czobor
authors.affiliation: 3Department of Psychiatry and Behavioral Sciences,New York Medical College,Valhalla,New York,USA.
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome
authors.affiliation: 4Research Triangle Institute International,Research Triangle Park,Durham,North Carolina,USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Van Dorn
mesh_terms: D000328:Adult; D000374:Aggression / Q000523:psychology*; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006791:Hostility; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010546:Perphenazine / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D000069348:Quetiapine Fumarate / Q000627:therapeutic use; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000031:analogs & derivatives / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D013469:Sulpiride; D000077582:Amisulpride; D010546:Perphenazine; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine